mash and semaglutide Metabolic dysfunction-associated steatotic liver disease (MASLD) affects nearly one in three adults worldwide, yet many cases remain undiagnosed until advanced fibrosis or cirrhosis develops. So, which patients should clinicians actually be screening? FDA Approves Semaglutide for MASH

These findings suggest that GLP-1 RAs could play a crucial role in the management of HFpEF, particularly in patients with obesity, by targeting the underlying inflammatory processes and contributing to better overall cardiovascular outcomes

Every trial participant who maintained strong body composition averaged 90 grams or more of protein daily, with no exceptions

Some clients feel increased energy and mental clarity shortly after treatment

95% CI 1.05, 0.87

Importantly, this occurred without worsening of fibrosis

With brand-name medications often costing upwards of $1,000 per month without insurance, many patients turn to their Flexible Spending Accounts (FSA) or Health Savings Accounts (HSA) to help cover the costs